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Amineptine is a new antidepressant agent 
with a molecular structure which is related to 
the tricyclic antidepressants but with a diffe-
rent pharmacological action. Neurochemi-
cal studies have shown that amineptine sti-
mulates dopaminergic neurotransmission in 
the mesolimbic and mesocortical systems by 
inhibition of the re-uptake of dopamine at 
presynaptic level (Mocaer, 1983; Labril 
et al., 1987; Offermeier et al., 1977 and 
Bonnet et al., 1987). 
In contrast to the other tricyclic anti-
depressants, amineptine in normal therapeu-
tic dosages, does not modify the release or the 
re-uptake of noradrenaline or serotonine. 
Although it is very difficult to extrapolate 
from neurotransmitter activities at cel'ular 
levels to pathological conditions or therapeu-
tical effects, there is some evidence that 
diminished dopaminergic activity is related 
to depressive syndromes, especially combined 
with psycho-motor retardation (Willner, 
1982, a, b, c). Amineptine has been used 
with success in the treatment of patients 
with reactive, neurotic, involutional and 
endogenous depressission (Kammerer et al., 
1981; Decker and Wayner, 1981; Deniker 
et al., 1982, Vauterin and Bazot, 1979; 
Bornstein, 1979; Lemoinc et al., 1981; Vain 
Amerongen, 1979; Porot et al., 1980 and 
Outes and Bosereton, 1983). 
MATERIAL AND METHOD 
Procedures and trial design 
In this six week open study both men 
and women, aged between 21 and 65 years, 
were included. Patients who fulfilled DSM-
III criteria lor Major Depression, single 
episode; Major Depression, recurrent; Bipo-
lar disorder, depressed or Dysthymic disorder 
(APA, 1980). Study was conducted at two 
centeres. 
Study subjects could be either hospitali-
zed or treated as out-patients. Exclusion 
criteria were: Huntington's chorea, severe or 
uncontrolled diabetes, severe disease of the 
liver, respiratory system, kidneys or heart, 
previous hepatitis related to amineptine, 
severe asthma or allergic conditions, cancer, 
disability or domicile which might inter-
fere with regular attendance, alcoholism, 
drug addiction, history of narrow-angle 
glaucoma, patients requiring medication 
which might induce enzymatic liver activity, 
pregnant women and women in the repro-
ductive period of life. 
At entry the subjects were assigned to 
amineptine using a flexible daily dosage of 
100 to 200 mg. This dosage could be adap-
ted individually to the severity of the depres-
sive symptoms. Additional medication with 
an anxiolytic, hypnotic or neuroleptic drug 
was allowed. 
AIM 
The purpose of our study was to evaluate 
the efficacy and acceptability of amineptine 
in depressive patients. 
Measurements of efficacy and safety 
Antidepressant activity and safety of 
amineptine were assessed on Day 0, 7, 14, 
21, 28, 35 and 42. 
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Clinical efficacy was assessed by : 
—The 21-item Hamilton Rating Scale of 
Depression-(HRSD) (Hamilton, 1967). 
—A global scale of severity of illness with 
a 5-point scale (very severe, severe, moderate, 
mild, nil). 
A clinical assessment of efficacy, was per-
formed at the end of the treatment (D42) 
with a 6-point rating scale (symptoms clea-
red, marked improvement, moderate improve-
ment, slight improvement, no change, worse). 
Clinical safety was studied using : 
—Sujective somatic complaints, body 
weight, heart rate, blood pressure (Phase 
VKorotkoff) both standing and supine, 
on Day 0, 7, 14, 21, 28, 35, and 42) 
—Laboratory tests ; haematology (hae-
moglobin, haematocrit, full blood count, 
including while cell differential), fasting 
blood glucose, blood urea, serum creatinin, 
serum alkaline phosphatase, and electro-
cardiogram, performed on DO and at the end 
of the treatment (D42). 
Study Population 
During a period of six months, 40 depre-
ssive patients meeting the inclusion criteria 
and exclusion criteria were thus included in 
two psychiatric centres at Bombay (20 sub-
jects) and Lucknow (20 patients;. The 
age of the study population ranged between 
22 and 65 years. The other demographic 
data of the study population are listed in 
Table I. All subjects included had a severe 
TABU
1. I. Dtmo%rapkk da'a nj study ><il,itct< at rntiy 
of the s'ndy {X=-t0< 
Men/Women 
Mean age 'years) 
Mean weight (kg) 
Professional .Status : 
I nemploycd/Retircd 
"lue collar 
White collar 
l-xrculive 'Professional 
Housewife. 
22/18 (55%/45%) 
40.9H-1-7 
53.6 -.1.7 
6 (15.0%) 
9 '22,5%) 
r, (15.0% > 
2 f 5.0",,, 
17 (12.0%; 
form of depression. Duration of the de-
pressive episodes before entry in the study 
ranged between 15 days to more thai: six 
years. Diagnoses at eritrv of the Mttdy accor-
ding to the DSM-I1I criteria are listed in 
Table II. In total 72.5",, were classified 
in as major depression or bipolar disorders. 
TABU: II. Diagnoses of study .< «/;•'<••/>, ami/ding In DSM 
III critcia at rntiy of t'<e study (\—4tl) 
Major Depression, single episode I 1 1*27.5% > 
Major Depression recurrenl 13(32.5",,' 
Bipolar Disorder, depressed 5 (l?.5",,i 
Dysthymic Disorder II (27.5%) 
Statistical analysis 
The time course for the antidepressant 
parameters has been evaluated wilh ihe non-
parametric test of Friedman. When time 
effect was significant this test was completed 
by a two-wav comparison ol the scores 
obtained at different moments. 
The biological and cardiovascular para-
meters were compared by a two-way analy-
ses of variance. When a time eflcct was 
significant the analysis was followed with the 
Newman-Keuls test. 
RESULTS 
Seventeen subjects were treated with 
amineptine alone. In 12 subjects aminep-
tine therapy was com'**iii'*d with hypnotic 
therapy (llura/epatn : 5: nitrazepam :7), 
while 15 subjects needed concomitant therapy 
with anxiolytic therapv ehlordia/e*>o\idc :7; 
diazepam: •>: lora/.cpatn:2;. 
One subject was dialed throughout the 
studv with propranolol because ol bengin 
essential tremors. 
Seven subjects were withdrawn Iroin the 
study, five because ol lack of improvement 
and two others due to poor follow up. 
Antidepressant efficacy 
The total score ol the Hamilton Rating 
Scale of Depression improved significantly 172  A. K. AGARWAL ET AL. 
TABLE III. Individual items of Hit Hamilton rating scale of depression at baseline and after 6 weeks treaimenl 
with amineptine indicated are average scoies + stm. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
18b 
19. 
20. 
21. 
Depressed mood 
Feelings of guilt 
Suicide 
Insomnia early 
Insomnia middle 
Insomnia late 
Work & Activities 
Retardation 
Agitation 
Anxiety psychic 
Anxiety somatic 
Somatic symptoms (Gastro-intestinal) 
Somatic symptoms (General) 
Genital symptoms 
Hypochondriasis 
Loss of weight 
Insight 
Diurnal variation 
. Severity of 18 
Depersonalisation/Derealisation 
Paranoid symptoms 
Obsessional and Compulsive symptoms 
Total Score 
n 
33 
33 
33 
33 
33 
33 
33 
33 
33 
33 
33 
33 
33 
33 
33 
33 
33 
33 
31 
33 
33 
33 
31 
Baseline 
m (± S.E.M) 
2.5 
0.8 
1.3 
1.3 
0.9 
1.4 
2.5 
1.1 
0.3 
2.1 
1.8 
1.2 
0.6 
1.2 
1.6 
0.4 
0.6 
0.5 
0.2 
0 
0 
0 
22.8 
(0.1) 
(0-2) 
(0.2) 
(0.1) 
(0.1) 
(0.1) 
(0.1) 
(0.2) 
(0.1) 
(0.1) 
(0.1) 
(0.1) 
(0.1) 
(0.1) 
(0.2) 
(0.1) 
(0.1) 
(0.1) 
(0.1) 
(0.7) 
End of 
treatment 
m(rl: S.E.M.) 
1.2 
0.2 
0.6 
0.4 
0.3 
0.6 
1.5 
0.3 
0.2 
1.3 
1.5 
0.6 
0.4 
0.8 
0.8 
0.2 
0.1 
0.2 
0.1 
0 
0 
0 
11.3 
(0.2) 
(0.1) 
(0.1) 
(0.1) 
(0.1) 
(0.1) 
(0.2) 
(0.1) 
(0.1) 
(0.2) 
(0-2) 
(0.1) 
(0.1) 
(0.1) 
(0.2) 
(0.1) 
(0.1) 
(0.1) 
(0.1) 
(1.5) 
p Value* 
{_ 0.001 
X. S. 
,/0.001 
^0.001 
0.015 
,/ 0.001 
/10.001 
/_ 0.001 
N. S. 
<i 0.001 
0.009 
0.018 
M.S. 
N. S. 
./0.001 
N. S. 
0.007 
N. S. 
N. S. 
N. S. 
N. S. 
N. S. 
zo.ooi 
*Th- time effect is based on the overall results of 6 weeks treatment. 
from 22.8 ±0.7 at week 0 to 11.9 ± 1.3 after 
6 weeks of treatment (p< 0.001). The 
improvement became significant after 2 
weeks of treatment (17.3 rb 1 ; p<0.05) and 
progressed further throughout the study 
(p<0.01). Subanalysis of the evolution of 
the individual items of this scale showed 
a significant improvement of 12 items, espe-
cially related to severity of depression, qua-
lity of sleep and psychomotor activity, anxiety 
and somatic symptoms (Table III). No 
individual item improved significantly within 
2 weeks of treatment. 
The score of the Clinical Global Evalua-
tion decreased progressively with a signi-
ficant difference with baseline values after 
4 weeks treatment (p<0.01). It suggests a 
gradual improvement of the average mood 
state of the subjects. 
Overall clinical assessment showed that 
21 out of 37 patients improved (56.8%) to a 
moderate degree or more, 21.6% of patients 
were reported to have slight improvement 
whereas 21.6% showed no change or worsen-
ing in their conditions (Table IV). 
A subsequent analysis of the Hamilton 
Rating Scale of Depression and the Clinical 
Global Evaluation was performed on the 
moderate to marked responders. 
The scores on Hamilton Rating Scale of 
Depression decreased from 23.4 ± 1.0 to 6.9 ± 
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TABLE IV. Results of the overall assessment scale of 
effiiwy in the patients that completed the study 
(,V=37) 
Symptoms cleared 
Marked improvement 
Moderate improvement 
slight improvement 
\"o change 
Worsening 
7 
5 
'.) 
8 
6 
2 
aw?;) 
(13.6%) 
(24.3%) 
(21.6%) 
(16.2%) 
( 5.4%) 
revaluation showed reduction from 2.3±0.1 
at the entry of the study to 0.6 ±0.2 at the 
end. 
Safety Parameters 
Complaints of patients 
Amineptine was well tolerated. In total 
11 side effects were reported that might be 
related to amineptine in our opinion. 
(Table V). The most frequent reported 
effect was dryness of the mouth of which 
three patients complained. One patient 
developed jaundice after three weeks of treat-
ment, but we could not establish the etiology 
of this symptom as this patient was lost to 
follow up. 
TABLE V. Reported adverse reactions that may 
be related to amineptine 
Dryness of mou'h 
Epigastric pain 
Constipation 
Jaundice 
Headache 
Insomnia 
Flushing 
Restlessness 
TOTAL 
3 
1 
2 
1 
1 
1 
t 
1 
11 
Effect on body weight 
There was a small but statistically signi-
ficant increase in body weight from 53.6 x 
1.7 Kg at baseline to 53.8 1 1.7 Kg at the end 
of treatment (p-^0.02;. 
Biological parameters 
Except for a small but significant increase 
in average haemoglobin values from 12.27 ± 
0.24 to 12.51 :0.26 g/lOOml (p<0.05), no 
significant clianges occurred in any of the 
tested biological parameters. A careful 
examination of individual data revealed no 
pathological changes in any of the patients 
that completed the study. 
Cardiovascular parameters 
No adverse cardiovascular effects were 
noted. Heart rate reduced significantly 
during the trial from 92.9.i; 1.2 at baseline 
to 79.9±0.6 at the end of treatment (p<0.01). 
Standing systolic blood pressure decreased 
significantly from 123.8 f.1.9 to 122.1 L 
1.9 mmHg at the end of treatment (p - 0.03). 
The other blood pressure values remained 
unchanged. The difference between supine 
and standing blood pressure did not change 
on amineptine. Case by case analysis of 
all cardiovascular parameters including 
E.C.G. recordings did not reveal any abnor-
mality. 
DISCUSSION 
This open study involved 40 patients 
with major depressions, bipolar disorders 
and dysthymic disorders according to DSM 
III criteria. 
From the start of therapy with aminep-
tine the mood level of the included patients 
showed a positive trend, the antidepressant 
effect of amineptine reached significance 
after two weeks therapy in the Hamilton 
Rating Scale of Depression nrtd after four 
weeks in the Clinical Global Evaluation. 
This relatively late onset of action is contra-
dictory to earlier studies with amineptine 
(Oules and Boscredon, 1983; Kammerer rt 
al., 1981; Dicker & Wagner, 1981; Dcni 
Keretal, 1982; Vauterin & Ba/.ot, 1979; 
Bomstrin, 1979; Lemoine et al., 1981; Van 
Amctongcn, 1979 and Perot et al., 1980). It 
is probably related to the low Marling dosages 174  A. K. AGARWAL ET AL. 
of amineptine used in the tirst week of treat-
ment during this trial. 
None of the individual items of the Hamil-
ton Rating Scale of Depression improved 
significantly within 2 weeks . of treatment, 
which suggests that the improvement of the 
quality of sleep and anxiety is related to the 
anti-depressant activity of amineptine and 
unrelated to the concomittant use of hypno-
tics or anxiolytics. 
In general amineptine was well tolerated 
in this study. The most frequent reported 
side effect was dryness of the mouth. 
Unfortunately, the patient who developed 
jaundice after three weeks of treatment was 
lost to follow-up and we were unable to estab-
lish the eliology of this symptom. As infec-
tious hepatitis is quite common in India, it 
is unlikely that this case of jaundice is related 
to drug therapy. It is well known however 
that hepatitis may occur during therapy 
with antidepressant drugs, including aminep-
tine, This side effect normally disappears 
after discontinuation of therapy (Yon 
and Anuras, 1975; Moskovitz et al., 1982; 
Andrieu et al., 1982). 
The small increase in average body 
weight during this trial may be a secondary 
result of increased appetite or due to the 
antidepressant effect of amineptine. 
The slight increase in haemoglobin value 
is of no clinical importance. As no other 
biological parameter changed, we may con-
clude that the biological tolerance of aminep-
tine was excellent. 
Amineptine caused a small decrease in 
heart-rate and standing systolic blood pres-
sure, but both changes arc of no clinical 
importance. All other cardiovascular para-
meters remained normal. 
There was no difference between standing 
and supine blood pressure levels and thus 
amineptine caused no postural hypotension. 
Other tricyclic antidepressants may cause 
postural hypotension in as many as 20% of 
patirnts (Glassman et al.. 1979> " 
The ECG recordings did not show any 
ST change, difference in QRS duration or T 
top inversion which suggests that aminep-
tine has no harmful effect on myocardial 
function and confirms the results obtained in 
other studies (Boehnert & Lovejoy, 1985 
and Agnoli et al., 1982). 
Amineptine seems to be a useful addi-
tion to the existing antidepressant drugs. 
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